3.5.1.18: succinyl-diaminopimelate desuccinylase
This is an abbreviated version!
For detailed information about succinyl-diaminopimelate desuccinylase, go to the full flat file.
Word Map on EC 3.5.1.18
-
3.5.1.18
-
haemophilus
-
l-captopril
-
peptidoglycan
-
meso-diaminopimelic
-
acetylornithine
-
metallohydrolase
-
drug development
-
medicine
- 3.5.1.18
- haemophilus
- l-captopril
- peptidoglycan
-
meso-diaminopimelic
- acetylornithine
-
metallohydrolase
- drug development
- medicine
Reaction
Synonyms
Cgl1109, DapE, dapE-encoded N-succinyl-LL-diaminopimelic acid desuccinylase, HiDapE, N-succinyl-L,L-diaminopimelic acid desuccinylase, N-succinyl-L-alpha,epsilon-diaminopimelic acid deacylase, Rv1202, S-DAP deacylase, SDAP, sDap desuccinylase, succinyl-diaminopimelate desuccinylase, succinyldiaminopimelate desuccinylase
ECTree
3.5.1.18 succinyl-diaminopimelate desuccinylaseAdvanced search results
results (
results (Inhibitors
Inhibitors on EC 3.5.1.18 - succinyl-diaminopimelate desuccinylase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
2-amino-6-[(2-methylpropanoyl)amino]heptanedioic acid
-
slight inhibition
2-thiopheneboronic acid
22.3% inhibition at 10 mM, non-competitive inhibitor
L-captopril
99.96%, 26.67% and 23.34% inhibition at 10 mM, 3 mM, and 1 mM
L-captopril
-
low-micromolar inhibitor, DapE is not the main target of L-captopril inhibition
additional information
-
no or poor inhibition by butylboronic acid, 4-carboxyphenylboronic acid, and 3-carboxyphenylboronic acid
-
additional information
design of structure-based, catalytic inhibitors, overview
-
additional information
-
design of structure-based, catalytic inhibitors, overview
-
additional information
-
mono-N-acyl derivatives of 2,6-diaminopimelic acid are no effective N-succinyl-L,L-diaminopimelic acid desuccinylase inhibitors, overview. No inhibition by 2-amino-6-(butanoylamino)heptanedioic acid, 2-amino-6-[(2,2-dimethylpropanoyl)amino]heptanedioic acid, 2-amino-6-(pentanoylamino)heptanedioic acid, 2-amino-6-(benzoylamino)heptanedioic acid, 2-amino-6-[(4-carboxybutanoyl)amino]heptanedioic acid, 2-amino-6-[(4-carboxy-3-methylbutanoyl)amino]heptanedioic acid, 2-amino-6-[(4-carboxy-3,3-dimethylbutanoyl)amino]heptanedioic acid, 2-amino-6-[(4-carboxy-2,2,3,3-tetrafluorobutanoyl)amino]heptanedioic acid, 2-amino-6-[[(2E)-4-methoxy-4-oxobut-2-enoyl]amino]heptanedioic acid, 2-amino-6-[(3-ethoxy-3-oxopropanoyl)amino]heptanedioic acid, and 2-amino-6-[[(2R)-4-methoxy-2-methylpent-4-enoyl]amino]heptanedioic acid
-
additional information
Tanimoto-based similarity searching in the PubChem Database with DapE substrate N-succinyl-LL-2,6-diaminoheptanedioate as a query molecule, followed by fragment-based docking approach using GLIDE XP identifies two potential substrate-competitive small molecule inhibitors of DapE. These new molecules may provide a starting point to search for novel therapeutics
-
additional information
-
Tanimoto-based similarity searching in the PubChem Database with DapE substrate N-succinyl-LL-2,6-diaminoheptanedioate as a query molecule, followed by fragment-based docking approach using GLIDE XP identifies two potential substrate-competitive small molecule inhibitors of DapE. These new molecules may provide a starting point to search for novel therapeutics
-
